Recent And Upcoming FDA Advisory Committee Meetings
Executive Summary
Recent and upcoming FDA advisory committee meetings and a summary of topics covered.
You may also be interested in...
Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin
Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for non-statin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel lipid-lowering agents.
Is Fabre-Kramer’s Gepirone Antidepressant Rising From The Dead After 8 Years?
Nothing has been heard about the major depressive disorder treatment since FDA issued a third “not approvable” letter in 2007; advisory committee to discuss NDA in December.
What’s Next? Five Things To Look Out For In October
Generics Bulletin previews the most notable and anticipated events for October 2023.